title: Hospital Case Volume Is Associated With Improved Survival for Patients With Metastatic Melanoma.
abstract: Hospital case volume has been shown to be a predictor of patient mortality for treatment for various cancers. The influence of hospital case volume on malignant melanoma survival and treatment utilization is unknown.
  
  
  
  We used the Surveillance, Epidemiology, and End Results-Medicare linked databases to identify patients aged 65 years or older diagnosed with metastatic melanoma between 2000 and 2009. We analyzed claims data to ascertain cancer treatment variation by hospital case volume. Overall survival was evaluated using propensity score methods.
  
  
  
  Among 1438 patients, 612 (42.6%) were treated in low-volume hospitals (≤5 patients) after receiving their diagnosis, 479 (33.3%) were treated in intermediate-volume hospitals (6 to 10 patients), and 347 (24.1%) were treated in high-volume hospitals (>10 patients). In Cox proportional hazards models, treatment in a high-volume hospital after propensity score adjustment was associated with a significant improvement in survival when adjusting for other characteristics (intermediate volume: hazard ratio [HR]=0.70, P=0.0007; high volume: HR=0.63, P<0.0001). Patients treated in high-volume hospitals were less likely to receive chemotherapy, surgery, and/or radiation therapy after a metastatic melanoma diagnosis.
  
  
  
  For patients diagnosed with metastatic melanoma, being treated in a high-volume hospital was associated with an improvement in survival and lower utilization of chemotherapy, immunotherapy, surgery, and radiation therapy.
authors.affiliation: Division of Radiation Oncology, M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Jinhai
authors.initials: J
authors.lastname: Huo
authors.forename: David R
authors.initials: DR
authors.lastname: Lairson
authors.forename: Xianglin L
authors.initials: XL
authors.lastname: Du
authors.forename: Wenyaw
authors.initials: W
authors.lastname: Chan
authors.forename: Jing
authors.initials: J
authors.lastname: Jiang
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Buchholz
authors.forename: B Ashleigh
authors.initials: BA
authors.lastname: Guadagnolo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D061847:Hospitals, High-Volume / Q000706:statistics & numerical data*; D061846:Hospitals, Low-Volume / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D006278:Medicare / Q000706:statistics & numerical data; D008545:Melanoma / Q000401:mortality* / Q000556:secondary / Q000628:therapy*; D057216:Propensity Score; D016016:Proportional Hazards Models; D011878:Radiotherapy / Q000706:statistics & numerical data; D018426:SEER Program; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-19-25
references.pmid: 12187164
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-3-18
references.pmid: 12187163
references.citation: Int J Colorectal Dis. 2013 Feb;28(2):191-6
references.pmid: 22842664
references.citation: Gynecol Oncol. 2010 Sep;118(3):262-7
references.pmid: 20573392
references.citation: JAMA. 2002 Oct 9;288(14):1719-20
references.pmid: 12365954
references.citation: J Clin Epidemiol. 2000 Dec;53(12):1258-67
references.pmid: 11146273
references.citation: J Palliat Med. 2011 Aug;14(8):929-39
references.pmid: 21767153
references.citation: Urol Oncol. 2010 May-Jun;28(3):243-50
references.pmid: 19395287
references.citation: J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9
references.pmid: 12772198
references.citation: J Pain Symptom Manage. 2007 Mar;33(3):238-46
references.pmid: 17349493
references.citation: N Engl J Med. 2001 Jul 19;345(3):181-8
references.pmid: 11463014
references.citation: World J Urol. 2011 Feb;29(1):73-7
references.pmid: 21132553
references.citation: Clin Gastroenterol Hepatol. 2008 Nov;6(11):1185-93
references.pmid: 18829393
references.citation: J Invest Dermatol. 2009 Jul;129(7):1666-74
references.pmid: 19131946
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-62-8
references.pmid: 12187170
references.citation: CA Cancer J Clin. 2009 May-Jun;59(3):192-211
references.pmid: 19414631
references.citation: JAMA. 2000 Dec 20;284(23):3028-35
references.pmid: 11122590
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-104-17
references.pmid: 12187175
references.citation: N Engl J Med. 2002 Apr 11;346(15):1128-37
references.pmid: 11948273
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-96-103
references.pmid: 12187174
references.citation: Gynecol Oncol. 2009 Dec;115(3):334-8
references.pmid: 19766295